Azitra (AZTR) Interest & Investment Income (2022 - 2026)
Azitra's (AZTR) quarterly Interest & Investment Income came in at $14719.0 in Q1 2026, down 60.39% YoY from $37164.0 in Q1 2025, and up 15.34% on a QoQ basis from $12761.0 in Q4 2025.
Azitra (AZTR) Interest & Investment Income (2022 - 2026) Analysis & Trends
Azitra (AZTR) has 5 years of Interest & Investment Income data on file, last reported at $14719.0 in Q1 2026.
- Quarterly Interest & Investment Income fell 60.39% year-over-year to $14719.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $47764.0 (down 68.6% YoY) and the FY2025 annual result came in at $70209.0, down 42.71% from the prior year.
- Interest & Investment Income climbed to $14719.0 in Q1 2026, from $12761.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $51287.0 in Q4 2024 to a low of $264.0 in Q2 2023.
- A 5-year average of $13334.7 and a median of $6216.0 in 2024 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2024 — Interest & Investment Income surged 12950.13% — and 2025, when it slumped 89.82%.
- Tracing AZTR's Interest & Investment Income over 5 years: stood at $762.0 in 2022, then tumbled by 48.43% to $393.0 in 2023, then surged by 12950.13% to $51287.0 in 2024, then tumbled by 75.12% to $12761.0 in 2025, then rose by 15.34% to $14719.0 in 2026.
- The last three Interest & Investment Income figures came in at $14719.0 (Q1 2026), $12761.0 (Q4 2025), and $4823.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Azitra | 2.53 Mn | 2.53 Mn | - | 74,661.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 74,661.00 |
| Mar 31, 2026 | 14,719.00 |
| Dec 31, 2025 | 12,761.00 |
| Sep 30, 2025 | 4,823.00 |
| Jun 30, 2025 | 15,461.00 |
| Mar 31, 2025 | 37,164.00 |
| Dec 31, 2024 | 51,287.00 |
| Sep 30, 2024 | 47,389.00 |
| Jun 30, 2024 | 16,268.00 |
| Mar 31, 2024 | 7,609.00 |
| Dec 31, 2023 | 393.00 |
| Sep 30, 2023 | 634.00 |
| Jun 30, 2023 | 264.00 |
| Mar 31, 2023 | 285.00 |
| Dec 31, 2022 | 762.00 |
| Sep 30, 2022 | 3,201.00 |
| Jun 30, 2022 | 335.00 |